Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study.

Trial Profile

Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2012

At a glance

  • Drugs Ataciguat (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms SERENEATI
  • Most Recent Events

    • 10 Aug 2012 Last checked against European Clinical Trials Database record.
    • 28 Apr 2012 Additional location Germany added as reported by European Clinical Trials Database record.
    • 19 Apr 2012 EudraCT reports actual initiation date is (30 Mar 2009), inclusion/exclusion criteria amended and this trial has been discontiuned in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top